A Phase 2 interventional study of mRNA-1083 in Influenza and SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 17 sites in 2 countries. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 11th largest by enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 17th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 7 · Phase 4 1
First in 2015; this study’s year is marked. 3 started in 2024.
This study's enrollment of 931 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 885 across the 23 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
2 of the studies in Influenza, Human by Moderna, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Influenza, Human by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
The study will be comprised of 2 parts, Parts 1 and 2. In Part 1, participants will be randomized into 4 study groups (Lots A, B, C, and D). Upon completion of Part 1, participants will be randomized into 2 study groups (Lots A and E) in Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 1.
Biological: mRNA-1083
Participants will receive mRNA-1083 Lot B as a single injection on Day 1 in Part 1.
Biological: mRNA-1083
Participants will receive mRNA-1083 Lot C as a single injection on Day 1 in Part 1.
Biological: mRNA-1083
Participants will receive mRNA-1083 Lot D as a single injection on Day 1 in Part 1.
Biological: mRNA-1083
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 2.
Biological: mRNA-1083
Participants will receive mRNA-1083 Lot E as a single injection on Day 1 in Part 2.
Biological: mRNA-1083
IM injection in a deltoid muscle.
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
The GMT has been measured by (Hemagglutination Inhibition) HAI assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.
Time frame: Day 29
Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2
The GMT has been measured by Pseudovirus Neutralization (PsVNA) assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.
Time frame: Day 29
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.
Time frame: From the day of study injection through 6 subsequent days (Up to 7 days)
Number of Participants With Unsolicited Adverse Events (AEs)
An AE was defined as any untoward medical occurrence, temporally associated with the use of study intervention, whether or not considered related to study intervention. Any solicited local or systemic adverse reaction that met SAE criteria was to be considered as AE.
Time frame: From the day of study injection through 27 subsequent days (Up to 28 days)
Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: From Day 1 to End of Study (Up to 6 Months)
Geometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.
Time frame: Day 29
Geometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2
The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.
Time frame: Day 29
Percentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
Seroconversion of antibodies for an influenza strain is defined as a post-vaccination anti-HA antibody value ≥1:40 if baseline is \<1:10 or a ≥4-fold rise in post-vaccination value if baseline is ≥1:10. The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.
Time frame: Day 29
Percentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-2
Seroresponse of SARS-CoV-2 antibodies is defined as a post-vaccination neutralizing antibody value ≥4×LLOQ if baseline is \<LLOQ, or a ≥4-fold rise in post-vaccination value if baseline is ≥LLOQ. The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.
Time frame: Day 29
| Milestone | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Started | 153 | 155 | 155 | 154 | 0 | 0 |
| Received study intervention | 153 | 155 | 153 | 154 | 0 | 0 |
| Completed | 145 | 147 | 152 | 145 | 0 | 0 |
| Not completed | 8 | 8 | 3 | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 5 | 1 | 7 | 0 | 0 |
| Withdrew: Randomized by mistake | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 | 1 | 0 | 0 |
| Withdrew: Other reasons | 1 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 158 | 156 |
| Received study drug injection | 0 | 0 | 0 | 0 | 158 | 156 |
| Completed | 0 | 0 | 0 | 0 | 147 | 141 |
| Not completed | 0 | 0 | 0 | 0 | 11 | 15 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 6 | 8 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 6 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 1 | 1 |
The GMT has been measured by (Hemagglutination Inhibition) HAI assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.
| Titer | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Influenza A/H1N1 | 268.4 (235.8 to 305.5) | 272.8 (239.5 to 310.9) | 280.5 (246.7 to 318.9) | 269.0 (236.7 to 305.8) | 148.9 (132.3 to 167.6) | 119.1 (105.6 to 134.3) |
| Influenza A/H3N2 | 207.0 (176.2 to 243.1) | 212.8 (180.9 to 250.5) | 217.3 (185.2 to 255.0) | 179.1 (152.7 to 210.1) | 94.3 (82.4 to 107.9) | 100.0 (87.2 to 114.6) |
| Influenza B/Victoria-lineage | 254.1 (216.5 to 298.3) | 268.8 (228.6 to 316.1) | 283.4 (241.7 to 332.2) | 241.6 (206.2 to 283.2) | 100.7 (86.9 to 116.8) | 91.7 (79.0 to 106.5) |
| Influenza B/Yamagata-lineage | 98.6 (86.6 to 112.3) | 118.5 (104.0 to 135.1) | 105.2 (92.5 to 119.7) | 100.1 (88.0 to 113.8) | 40.4 (36.0 to 45.4) | 40.2 (35.7 to 45.3) |
The GMT has been measured by Pseudovirus Neutralization (PsVNA) assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.
| Titer | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2 | 3735.0 (3177.7 to 4390.0) | 3633.5 (3086.4 to 4277.6) | 4083.0 (3478.6 to 4792.3) | 3316.2 (2826.9 to 3890.3) | 3940.5 (3342.4 to 4645.7) | 3587.9 (3035.0 to 4241.6) |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.
| Participants | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Any Solicited ARs | 128 | 122 | 121 | 120 | 99 | 99 |
| Solicited Local ARs | 117 | 111 | 113 | 108 | 90 | 81 |
| Solicited Systemic ARs | 108 | 106 | 98 | 99 | 80 | 84 |
An AE was defined as any untoward medical occurrence, temporally associated with the use of study intervention, whether or not considered related to study intervention. Any solicited local or systemic adverse reaction that met SAE criteria was to be considered as AE.
| Participants | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 13 | 13 | 13 | 11 | 6 | 5 |
A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| MAAEs | 19 | 16 | 16 | 18 | 7 | 7 |
| AESIs | 1 | 0 | 1 | 0 | 2 | 0 |
| SAEs | 1 | 1 | 2 | 1 | 2 | 1 |
| AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 |
The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.
| Ratio | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Influenza A/H1N1 | 2.35 (2.06 to 2.67) | 2.42 (2.12 to 2.77) | 2.58 (2.25 to 2.96) | 2.51 (2.17 to 2.91) | 2.53 (2.20 to 2.92) | 2.16 (1.93 to 2.42) |
| Influenza A/H3N2 | 4.02 (3.39 to 4.77) | 4.32 (3.61 to 5.16) | 4.21 (3.57 to 4.97) | 3.61 (3.08 to 4.23) | 2.55 (2.26 to 2.87) | 2.70 (2.31 to 3.17) |
| Influenza B/Victoria-lineage | 3.79 (3.19 to 4.51) | 3.98 (3.26 to 4.87) | 4.47 (3.69 to 5.42) | 3.97 (3.36 to 4.7) | 2.77 (2.36 to 3.26) | 2.64 (2.26 to 3.09) |
| Influenza B/Yamagata-lineage | 2.34 (2.10 to 2.61) | 2.86 (2.45 to 3.35) | 2.55 (2.19 to 2.97) | 2.50 (2.20 to 2.85) | 1.94 (1.73 to 2.16) | 2.03 (1.77 to 2.34) |
The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.
| Ratio | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Geometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2 | 9.45 (7.40 to 12.06) | 11.95 (9.10 to 15.69) | 12.05 (9.44 to 15.37) | 9.67 (7.82 to 11.96) | 12.22 (9.48 to 15.74) | 10.58 (8.23 to 13.61) |
Seroconversion of antibodies for an influenza strain is defined as a post-vaccination anti-HA antibody value ≥1:40 if baseline is \<1:10 or a ≥4-fold rise in post-vaccination value if baseline is ≥1:10. The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.
| Percent of participants | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Influenza A/H1N1 | 29.3 (22.0 to 37.3) | 31.9 (24.4 to 40.2) | 38.9 (31.1 to 47.2) | 32.7 (25.2 to 40.8) | 30.5 (23.4 to 38.4) | 22.8 (16.3 to 30.4) |
| Influenza A/H3N2 | 51.7 (43.3 to 60.0) | 49.3 (40.9 to 57.8) | 57.7 (49.4 to 65.8) | 47.3 (39.1 to 55.6) | 35.1 (27.6 to 43.2) | 34.2 (26.7 to 42.4) |
| Influenza B/Victoria-lineage | 46.9 (38.7 to 55.3) | 47.2 (38.9 to 55.7) | 56.4 (48.0 to 64.5) | 52.0 (43.7 to 60.2) | 40.3 (32.3 to 48.6) | 34.9 (27.2 to 43.3) |
| Influenza B/Yamagata-lineage | 28.6 (21.4 to 36.6) | 38.9 (30.9 to 47.4) | 31.5 (24.2 to 39.7) | 31.3 (24.0 to 39.4) | 17.5 (11.9 to 24.5) | 25.5 (18.7 to 33.3) |
Seroresponse of SARS-CoV-2 antibodies is defined as a post-vaccination neutralizing antibody value ≥4×LLOQ if baseline is \<LLOQ, or a ≥4-fold rise in post-vaccination value if baseline is ≥LLOQ. The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.
| Percent of participants | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| Percentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-2 | 72.1 (64.1 to 79.2) | 72.9 (64.9 to 80.0) | 73.8 (66.0 to 80.7) | 73.3 (65.5 to 80.2) | 71.4 (63.6 to 78.4) | 69.8 (61.7 to 77.0) |
Collected over All-cause mortality was collected throughout the entire period of the study. SAEs were collected from the time of informed consent through Day 181/EOS. Other adverse events were collected from the time of injection through 28 days after injection, unless they met the criteria for SAEs, AESIs, MAAEs or AEs leading to discontinuation (which were collected from day 1 through Day 181/EOS).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Group 1 - mRNA-1083 Lot A | 0/153 (0%) | 1/153 (0.7%) | 0/153 (0%) |
| Part 1 Group 2 - mRNA-1083 Lot B | 0/155 (0%) | 1/155 (0.6%) | 0/155 (0%) |
| Part 1 Group 3 - mRNA-1083 Lot C | 0/155 (0%) | 2/153 (1.3%) | 0/153 (0%) |
| Part 1 Group 4 - mRNA-1083 Lot D | 0/154 (0%) | 1/154 (0.6%) | 0/154 (0%) |
| Part 2 Group 5 - mRNA-1083 Lot A | 0/158 (0%) | 2/158 (1.3%) | 0/158 (0%) |
| Part 2 Group 6 - mRNA-1083 Lot E | 0/156 (0%) | 1/156 (0.6%) | 0/156 (0%) |
| Event | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E |
|---|---|---|---|---|---|---|
| DiverticulitisInfections and infestations | 1/153 | 0/155 | 0/153 | 0/154 | 0/158 | 0/156 |
| Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/153 | 0/155 | 1/153 | 0/154 | 0/158 | 0/156 |
| Alcohol withdrawal syndromePsychiatric disorders | 0/153 | 0/155 | 1/153 | 0/154 | 0/158 | 0/156 |
| Post procedural infectionInfections and infestations | 0/153 | 0/155 | 0/153 | 1/154 | 0/158 | 0/156 |
| OrchitisInfections and infestations | 0/153 | 1/155 | 0/153 | 0/154 | 0/158 | 0/156 |
| West Nile viral infectionInfections and infestations | 0/153 | 1/155 | 0/153 | 0/154 | 0/158 | 0/156 |
| Foot fractureInjury, poisoning and procedural complications | 0/153 | 0/155 | 0/153 | 0/154 | 0/158 | 1/156 |
| UrosepsisInfections and infestations | 0/153 | 0/155 | 0/153 | 0/154 | 1/158 | 0/156 |
| Status epilepticusNervous system disorders | 0/153 | 0/155 | 0/153 | 0/154 | 1/158 | 0/156 |
| Atrial flutterCardiac disorders | 0/153 | 0/155 | 0/153 | 0/154 | 1/158 | 0/156 |
The Randomization Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.
| Age, Continuous(Years) | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E | Total |
|---|---|---|---|---|---|---|---|
| Mean | 58.2 ± 4.27 | 57.1 ± 4.24 | 56.7 ± 4.44 | 57.3 ± 4.41 | 57.2 ± 4.19 | 56.8 ± 4.25 | 57.2 ± 4.32 |
| Sex: Female, Male(Participants) | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E | Total |
|---|---|---|---|---|---|---|---|
| Female | 90 | 96 | 94 | 109 | 96 | 89 | 574 |
| Male | 63 | 59 | 61 | 45 | 62 | 67 | 357 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 74 | 76 | 77 | 76 | 117 | 116 | 536 |
| Not Hispanic or Latino | 78 | 79 | 78 | 75 | 38 | 40 | 388 |
| Unknown or Not Reported | 1 | 0 | 0 | 3 | 3 | 0 | 7 |
| Race/Ethnicity, Customized(Participants) | Part 1 Group 1 - mRNA-1083 Lot A | Part 1 Group 2 - mRNA-1083 Lot B | Part 1 Group 3 - mRNA-1083 Lot C | Part 1 Group 4 - mRNA-1083 Lot D | Part 2 Group 5 - mRNA-1083 Lot A | Part 2 Group 6 - mRNA-1083 Lot E | Total |
|---|---|---|---|---|---|---|---|
| White | 125 | 120 | 117 | 122 | 123 | 109 | 716 |
| Black or African American | 22 | 28 | 31 | 27 | 32 | 45 | 185 |
| Asian | 2 | 1 | 3 | 2 | 0 | 2 | 10 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Multiple | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Other | 1 | 2 | 1 | 2 | 0 | 0 | 6 |
| Unknown/Not Reported | 2 | 3 | 3 | 0 | 2 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2024 to primary completion in Sep 2025, 14 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 14 months is above that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MRNA-1083